April-Monn, S.L.; Andreasi, V.; Schiavo Lena, M.; Sadowski, M.C.; Kim-Fuchs, C.; Buri, M.C.; Ketkar, A.; Maire, R.; Di Domenico, A.; Schrader, J.;
et al. EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). Cancers 2021, 13, 5014.
https://doi.org/10.3390/cancers13195014
AMA Style
April-Monn SL, Andreasi V, Schiavo Lena M, Sadowski MC, Kim-Fuchs C, Buri MC, Ketkar A, Maire R, Di Domenico A, Schrader J,
et al. EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). Cancers. 2021; 13(19):5014.
https://doi.org/10.3390/cancers13195014
Chicago/Turabian Style
April-Monn, Simon Leonhard, Valentina Andreasi, Marco Schiavo Lena, Martin Carl Sadowski, Corina Kim-Fuchs, Michelle Claudine Buri, Avanee Ketkar, Renaud Maire, Annunziata Di Domenico, Jörg Schrader,
and et al. 2021. "EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs)" Cancers 13, no. 19: 5014.
https://doi.org/10.3390/cancers13195014
APA Style
April-Monn, S. L., Andreasi, V., Schiavo Lena, M., Sadowski, M. C., Kim-Fuchs, C., Buri, M. C., Ketkar, A., Maire, R., Di Domenico, A., Schrader, J., Muffatti, F., Doglioni, C., Partelli, S., Falconi, M., Perren, A., & Marinoni, I.
(2021). EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). Cancers, 13(19), 5014.
https://doi.org/10.3390/cancers13195014
